Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6232MR)

This product GTTS-WQ6232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6232MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ183MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ3473MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ3887MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ15427MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ8699MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ6415MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ12854MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ7668MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW